Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected

Related Experiment Video

Updated: Oct 20, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

D T Dieterich1, J M Purow, R Rajapaksa

  • 1Liberty Medical L.L.P., New York, NY 10016, USA.

Seminars in Liver Disease
|June 1, 1999
PubMed

Insights

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection impacts HCV progression. Combination therapy with rIFN-alpha 2b/ribavirin is being studied for its efficacy in co-infected patients.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) share transmission routes, leading to frequent co-infections.
  • HIV co-infection complicates HCV diagnosis, viremia assessment, liver disease severity, and cirrhosis progression.
  • The impact of HCV co-infection on HIV disease progression remains largely undetermined.

Purpose of the Study:

  • To investigate the efficacy of combination therapy with recombinant interferon alfa-2b (rIFN-alpha 2b) and ribavirin in patients co-infected with HCV and HIV.
  • To test the hypothesis that this combination therapy offers benefits to individuals with both HCV and HIV.

Main Methods:

  • A double-blind, placebo-controlled study design is employed.
  • The study involves patients co-infected with both the hepatitis C virus and the human immunodeficiency virus.
  • Therapeutic efficacy is assessed through a rigorous, controlled investigation.

Main Results:

  • The study is currently underway, and results are pending.
  • Data collection and analysis are in progress to evaluate treatment outcomes.
  • The primary outcomes related to viral load, liver histopathology, and disease progression will be determined.

Conclusions:

  • The study aims to determine if combination rIFN-alpha 2b/ribavirin therapy is beneficial for HCV/HIV co-infected patients.
  • Findings will clarify the therapeutic potential of this combination regimen in a co-infected population.
  • The results are expected to inform clinical management strategies for individuals with dual viral infections.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...